

## Board of Directors Meeting in Public - Cover Sheet

<b>Subject:</b>	<b>Research and Development Performance Report – 2022/23</b>		<b>Date:</b> 6 <sup>th</sup> April 2023	
<b>Prepared By:</b>	Terri-Ann Sewell Research Operations Manager			
<b>Approved By:</b>	Elizabeth Gemmill, Director of Research and Innovation			
<b>Presented By:</b>	Terri-Ann Sewell Research Operations Manager			
<b>Purpose</b>				
To present the Research and Innovation Annual Performance Report		<b>Approval</b>		
		<b>Assurance</b>		
Update and assurance on performance KPI's and financial position		<b>Update</b>	X	
To give a brief overview on the plan to achieve actions within the new R&I strategy.		<b>Consider</b>		
<b>Strategic Objectives</b>				
<b>To provide outstanding care</b>	<b>To promote and support health and wellbeing</b>	<b>To maximise the potential of our workforce</b>	<b>To continuously learn and improve</b>	<b>To achieve better value</b>
X		X	X	X
Indicate which strategic objective(s) the report support				
<b>Identify which principal risk this report relates to:</b>				
PR1	Significant deterioration in standards of safety and care			
PR2	Demand that overwhelms capacity			
PR3	Critical shortage of workforce capacity and capability			
PR4	Failure to achieve the Trust's financial strategy			
PR5	Inability to initiate and implement evidence-based Improvement and innovation			
PR6	Working more closely with local health and care partners does not fully deliver the required benefits			
PR7	Major disruptive incident			
PR8	Failure to deliver sustainable reductions in the Trust's impact on climate change			
<b>Committees/groups where this item has been presented before</b>				
None				
<b>Acronyms</b>				
<b>List all acronyms used within the report.</b>				
DPR = Divisional Performance Review				
ICB = Integrated Care Board				
CRN= Clinical research Network				
EMCRM= East Midlands Clinical Research Network				
NIHR= National Institute Clinical Research				
R&I=Research and Innovation				
<b>Executive Summary</b>				
<b>Performance Metrics</b>				
<ul style="list-style-type: none"> <li>2,667 participants recruited into research studies compared to 1,477 in 21/22, 66 studies on the SFH portfolio</li> <li>Confirmed £774,623.16 EMCRN 2023/24 budget.</li> <li>Commercial income at £ 147,747.70</li> </ul>				

### **Patient Experience**

- 96% of participants Agree/Strongly Agree their participation in Research has been valued
- 96% of participants would consider taking part in Research again
- All Participants Agree/Strongly Agree that they have been treated with courtesy and respect

### **Research highlights 22-23**

1. CRF space secured and building work to commence Summer 2023
2. Leading Research – Chief Investigator and Sponsor for a grant-funded multi-site study successful, results to be published June 2023.
3. Influencing and informing through the Nottinghamshire ICS Research Partners Group
4. Development of formal partnership with NTU
5. R&I commenced collaborative working with Primary Care to support the development, operation and delivery of clinical research and training across Mansfield and Ashfield.
6. Launched R&I new strategy 22-27
7. R&I 1<sup>st</sup> apprentice commenced placement within the department, allowing us to build our workforce and create career opportunities.